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1. Introduction 
1.1 Impact of therapeutics on survival 
Survival rates to hospital discharge for a neonate with a diagnosis of congenital 
diaphragmatic hernia (CDH) appear to have improved remarkably when comparing reports 
of 82-93% survival out of single institutions to the overall survival rate of 69% from tertiary 
centers in the Congenital Diaphragmatic Hernia Study Group (CDHSG). Others continue to 
dispute such outstanding gains, attributing them both to patient recruitment and a case 
selection bias at tertiary referral centers (Stege et al., 2004). In contrast, significantly lower 
survival rates of 54-56% have been reported from population-based studies in the UK and 
Australia despite their implementation of the same strategy of presurgical stabilization, 
permissive hypercapnea and gentilation with high frequency ventilator modes (Levison, 
2006). Population based studies typically include more nonsurvivors than tertiary referral 
centers who capture only those who survived to arrival the other caveat is how to best track 
all those diagnosed prenatally. 
The UK and Australian experience was similarly reflected in a US population-based study 
using the KIDS’ Inpatient Database, in which overall survival was 66% (Sola et al., 2010). 
Strikingly, the postoperative survival in the KIDS’ Database was much higher at 86% 
which reflects the degree of case selection bias involved in those offered surgical repair. 
This discordance supports those who argue the higher survival reports out of single 
institutions often reflect an underlying unintended case selection bias. Despite all the 
advances in intensive care management of diaphragmatic hernias and ventilation of 
critically ill neonates, there remains a >35% of live-born infants with a CDH who do not 
survive to transport, making the diagnosis of CDH accountable for >1% of all annual 
infant mortality (Clark et al., 1998) and the highest in-hospital neonatal mortality of all 
birth defects (CDC, 2007).  
Clearly a subset of children with CDH remains predisposed to fatality despite the 
availability of novel therapies. Thus being able to predict which subset is most likely to 
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benefit from experimental or more aggressive therapies, as well as the consideration of 
withdrawal of care when suitable, would be remarkably useful to best target novel 
therapeutics for best benefit. In fact now there are many novel therapies directed at the high 
risk subset and liberally utilized given the inability to risk stratify patients. These novel 
therapeutics include the selective use of ECMO (Khan & Lally, 2005), pulmonary 
vasodilators such as inhaled nitric oxide (Okuyama et al., 2002; Finer & Barrington, 2001), 
and sildenafil (Hunter et al., 2009), permissive hypercapnea and high frequency oscillatory 
ventilation (Miguet et al., 1995), treatment at high volume centers (Stege et al., 2004), fetal 
surgery/ tracheal occlusion without proven survival advantage (Harrison et al., 2003), and 
the futuristic application of partial liquid ventilation (Hirschl, 2004). Other therapies often 
utilized, such as the use of exogenous surfactant, have not been shown to improve survival 
rates in the premature infant with CDH; although, they have not been analyzed in a 
randomized control trial to fully prove efficacy (Lally et al., 2004). 
2. Defect size: Prognostic relevance 
The coexistence of marked pulmonary hypertension and pulmonary hypoplasia are the key 
factors identifying the subset of infants that are more likely to die or survive with significant 
morbidity. The ability to identify prenatally those with problematic pulmonary 
hypertension and hypoplasia has not yet been realized. There are many indirect metrics for 
prenatal predictors of mortality which at best can estimate postnatal outcomes with variable 
accuracy. Those prenatal predictors of mortality include fetal liver position (Kunisaki et al., 
2008; Kitano et al. 2005; Hedrick et al., 2007), fetal lung volumes (Nishie et al., 2009) and 
lung area-to-head ratios (LHR) (Bretelle et al., 2007; Deprest et al., 2009). Notably all of these 
measures are proxies for the severity of underlying pulmonary hypoplasia secondary to the 
degree of visceral herniation. In an isolated left CDH, liver position is the best prenatal 
predictor of outcome. In those with liver up, ECMO was required in 80% of fetuses 
compared to 25% for those with liver down: survival rate was 45% for the liver up subset, 
compared to 93% for those with liver down (Hedrick et al., 2007). In similar fashion, a low 
LHR (<1.0) predicted an increased incidence of ECMO (75%) with a lower survival rate 
(35%) (Hedrick et al., 2007), but the LHR was not useful in those <24 weeks GA (Yang et al, 
2007). There are other factors used to predict survival which include birth weight >2.5 Kg 
(Casaccia et al., 2006), and coexistence of chromosomal and cardiac anomalies (Graziano et 
al., 2006; Witters et al., 2001; Hilfiker et al., 1998). The most common chromosomal 
anomalies identified in CDH were trisomies 13, 18, and 21, the most common syndrome was 
Fryns syndrome, and either a hypoplastic left heart syndrome, coarctation of the aorta, or 
tetralogy of fallot for the complex heart disease identified. 
The size of the defect is the best corollary for the degree of pulmonary hypoplasia. In vivo 
CDH animal models have demonstrated the association between varying the size of the 
defect and the resultant degree of pulmonary hypoplasia in both lambs and toxicological 
rodent models, where the gestational timing of the insult is the factor determining defect 
size and outcome (Hilfiker et al., 1998). The CDHSG identified the size of the 
diaphragmatic hernia defect as the major factor influencing outcome based on a 9 year 
multi-institutional registry of 3062 CDH patients (Lally et al., 2007). Notably those with a 
primary repair had a 95% survival rate compared to those requiring a patch repair at 79% 
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in contrast to an overall survival rate of 69% for all comers. Thus a patch repair has 
become synonymous with larger defect sizes. Among those requiring a patch repair, those 
with the largest defect possible - diaphragm agenesis, had the worst odds of survival at 
57% with an odds ratio of 14.04 times the mortality of those who underwent a primary 
repair (Singh et al., 1999). Neonates with a diaphragm agenesis are well known to be 
associated with a high mortality (Brindle et al., 2011).  
The significance of the diaphragm defect was confirmed by the Canadian Pediatric Surgery 
Network (CAPSNet) in a 5-year 212 patient database which showed that a patch repair was 
the only significant predictor of mortality with an odds ratio of 17:1 (Skargard et al., 2005). 
Those requiring patch repairs were independently associated with secondary morbidities 
such as the number of ventilator days and the need for oxygen at discharge. The Canadian 
study was illustrative given the absence of other confounding variables to which to attribute 
the mortality risk. The subset requiring a patch repair did not also have a higher incidence 
of other risk variables such as birth weight, gestational age, or the presence of cardiac or 
chromosomal anomalies. Instead in CAPSNet, those requiring a patch repair differed from 
those not requiring a patch repair strictly only by their need for ECMO and SNAP-II score, 
both measures of disease severity. The SNAP-II score, the score for neonatal acute 
physiology, is a well described and validated metric for the predictor of mortality in CDH. 
Thus the need for a patch repair is our best proxy for defect size, and by showing a higher 
mortality risk associated with patch repair , defect size is the best surrogate marker for the 
severity of pulmonary hypoplasia.  
The spectrum of defect sizes parallels the prenatal timing of initial detection prenatally 
and the underlying degree of associated pulmonary hypoplasia. Prenatally the degree of 
visceral herniation has been a good proxy for the size of the defect: the grade of herniation 
of the stomach into the chest (Kitano et al., 2011), herniation of the liver into the chest 
(Mullassery et al., 2010), herniation of the liver combined with the LHR for prediction of 
ECMO usage and mortality (Hedrick et al., 2007). All these prenatal measurements are 
used as predictors of outcome and are the best proxies for the size of the defect and the 
severity of underlying pulmonary hypertension. The converse is also true that there is a 
subset of left sided CDH neonates who have no evidence of visceral herniation in utero 
and have a remarkably higher survival rate, lower prosthetic graft rate, and lower ECMO 
utilization compared to the control group (Valfre et al., 2011). This finding documented 
what was well recognized clinically - that the presentation of a CDH postnatally is 
associated with smaller defects, a lower need for prosthetic graft repairs than those who 
present early in gestation, and better outcomes. To date the actual defect size remains 
immeasurable by prenatal or postnatal imaging. Although defect size is singularly 
predictive of outcome in both overall survival (Singh et al.,1999; Skargard et al., 2005) and 
longterm morbidities (Raval et al., 2011), such as gastroesophageal reflux, altered 
pulmonary function and poor auxological outcomes, a numeric value for the defect size 
has not been accurately recorded in most studies or tracked in registries. Similarly there is 
no identified cut-off value that defines the large defects or agenesis. Efforts continue to 
focus ideally on attempting to determine defect size prenatally or preoperatively to risk 
stratify patients and better match high risk patients with high risk therapies, with 
improved counseling and avoiding risky therapies in low risk patients. 
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3. Patch repairs: Synthetics versus Biologics 
3.1 Primary repair 
Primary repair is the desired standard for the closure of the diaphragmatic defect. Due to all 
the advances above, the cohort of more complicated repairs is increasing and long term follow 
up is available on the durability of various types of repair. In all cases, closure needs to ensure 
durability to best avoid re-herniation since re-operative surgery is not trivial in these children. 
The percentage of neonates undergoing repair is not clear, since different centers vary as to 
patient recruitment and which patients are deemed unsalvageable for surgical intervention. 
Not all such patients are included in registries. For an approximate estimate of the percentage 
repaired, analysis of the KIDS’ Inpatient Database limited to all patients less than 8 days of age 
admitted to any hospital with a diagnosis of CDH identified 2774 patients, of which only 1095 
underwent operative repair (Sola et al., 2010). Thus approximately a third of all neonates with 
a CDH are offered surgical repair. This analysis that a third were actually offered surgical 
repair was confirmed by a different KIDS’ Database analysis (Raval et al., 2011). Thus not all 
CDH neonates are offered repair, which implies those that are offered repair represent a case 
selection bias. In contrast, the CDHSG registry with 3062 live born CDH infants from tertiary 
institutions reported a larger percentage of up to 82.4% of those tracked in the registry were 
surgically repaired: 43% had a primary repair, 22.1% had a patch repair and 15% had complete 
agenesis (Singh et al., 2009).  
3.2 Synthetic and biologics 
Given the expected variations of surgical preference in determining whether a patch is used, 
there is a trend to liberally use patches to avoid tension and compartment syndromes (Loff 
et al., 2005; Bax and Collins, 1984). So some elect patch repair to improve physiologic results 
and others use patches only when primary repair cannot be physically achieved. Current 
practice is to create a tension-free closure such that prosthetic patches are used only when a 
defect is not amenable to a primary repair, after mobilizing the posterior diaphragmatic leaf, 
or as in cases of agenesis. The most common material used in prosthetic patches is 
polytetrafluoroethylene (PTFE: Gore-tex® [WL Gore and Associates, Flagstaff, AZ]); other 
prosthetic materials have included composite grafts with Goretex®, SILAS-TIC© (Dow 
Corning, Midland, MI), Dacron, polypropylene and fluorinated polyester but none of these 
have been used as frequently as Gore-Tex. The concern with prosthetics is their inability to 
accommodate thoracic growth leading to chest restriction, chest wall deformity (Greig & 
Azmy, 1990), and reherniation (Hajer et al., 1998). PTFE induces no tissue ingrowth and 
incites a high inflammatory response with essentially no biologic fusion to the surrounding 
diaphragmatic muscle.  
Numerous biologics have been applied to CDH defects to create a lattice, allowing for tissue 
ingrowth of autologous tissue (see Table 1). Biologics ideally, with tissue incorporation, 
would be able to avoid the reherniation rates characteristic of prosthetic patches and the 
scoliosis from the inability of a prosthetic to compensate for age-related growth of the 
thoracic cavity. The most commonly used acellular bioprosthetic patches include Surgisis-
Gold (Cook Biotech, Lafayette, IN), Permacol (Tissue Science Laboratories Inc, Andover, 
Mass), Alloderm (LifeCell Inc, Branchburg, NJ), or recent composites with a synthetic 
sandwiched as an overlay to a bioprosthetic, such as Gore-tex® and Surgisis®(See Figure 
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1D) Prior bilayer patches incorporated both Gore-tex® and Marlex® which demonstrated 
only one recurrence (3.5%) (Riehle et al., 2007) which suggested a benefit of sandwiching a 
synthetic with a monofilament mesh to induce tissue incorporation. 
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Table 1. Types of bioprosthetic materials for grafts 
Synthetic patch repairs emerged historically as the predominant method of tension-free 
closure of defects not amenable to primary repair (Levison et al., 2006). Despite three 
decades of experience with synthetic patches, which offer a superb short term solution, 
recurrence rates are reported as high as 41% -46% at a median follow up of 12 months (Moss 
et al., 2001; Jancelewicz et al., 2010), compared to 10-22% rate following primary closure in 
long-term survivors (Jancelewicz et al., 2010; Cohen & Reid, 1981). Long-term studies 
showed that prosthetic grafts can result in recurrences in up to 50% of patients by 3 years of 
age (Moss et al., 2001). The risk factors associated with an increased risk of recurrence in 
graft repairs include all factors discussed earlier that are associated with a worse disease 
severity, such as right side CDH laterality, ECMO therapy, size and need for a patch (Hajer 
et al., 1998).  
Only the history of a patch repair was independently predictive of a subsequent 
diaphragmatic hernia recurrence when compared to multiple prenatal markers of CDH 
severity in a multivariant regression analysis (Jancelewicz et al., 2010). The higher rates of 
recurrence in synthetic patch repairs are thought to be secondary to a lack of tissue 
incorporation and inability to accommodate growth, so that tension over time causes the 
patches to separate from the thoracic wall as well as lead to chest wall deformities. Notably 
there is an increased prevalence of chest deformities in 50% of patients by 3 years of age, 
equivalent to the incidence of recurrences (Vanamo et al., 1996). In fact there is a bimodal 
distribution of recurrences with Gore-Tex®: an early peak at 2 months and a later peak at 20 
months (Moss et al., 2001). This bimodal distribution of graft failure has been confirmed in 
other studies (Mitchell et al., 2008).  
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Fig. 1. Comparison of Gore-tex® and Surgisis®. A. Gortex patch sewn in situ, B. 
Thoracoscopic view of Surgisis® patch in situ. C. Technique of thoroscopically introducing a 
patch, D. A modified patch combining Gore-Tex (nonabsorbable mesh) and Surgisis 
(biodegradable prosthetic material) as a bilayer composite graft. (Courtesy of Dr. Mark 
Wulkan at Emory University School of Medicine & Emory Children's Center) 
Bioprosthetics have been widely applied and successful in a variety of hernia repairs and 
closures of abdominal wall defects. They provide a temporary acellular scaffold that 
supports native tissue ingrowth and ability to accommodate growth. Since these 
bioprosthetics are acellular, they are nonimmunogenic. Given the high recurrence rates 
associated with Gore-Tex®, one study compared Surgisis® (a 4- or 8- ply porcine-derived 
extracellular matrix from small intestine submucosa) to Gore-Tex® in 72 newborns, 
reporting no significant difference in recurrence rates (38% and 44%, respectively: Grethel EJ 
et al., 2006). Graft failures occurred early with 92% of Surgisis® failures and 75% of Gore-
Tex® failures within 1 year. A Surgisis® repair was associated with higher frequency of 
operative bowel obstruction, (Jancelewicz et al., 2010; St. Peter SD et al., 2007) and was 
possibly proinflammatory (Baroncello JB et al., 2008). In a recent in vivo porcine model, 
Surgisis® resulted in better tissue integration than PTFE, enhanced incorporation of skeletal 
muscle in replacement of the acellular graft with higher collagen-forming fibroblasts, and 
lower fibrotic reaction (Gonzalez et al., 2011). In contrast, PTFE induced a thick fibrotic 
capsule consistent with an inflammatory reaction that exceeded that of Surgisis®. Perforated 
and 8-ply Surgisis® is currently being trialed in composite grafts with Gore-Tex® (Fig 1). 
Remodeling of collagen-based patches in CDH applications has been analyzed in animal 
models to compare Surgisis®, a porcine intestinal submucosa to Gore-Tex® (Lantis et al., 
2000). The collagen-based repairs showed more integration, increased vascularization, 
fibroblastic ingrowth, and less inflammation compared to the high inflammatory reaction at 
the PTFE-diaphragmatic interface. This proinflammatory reaction along the synthetic to 
diaphragm interface may explain the recurrence rates seen.  
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Fig. 2. Intrathoroscopic Visualization of a Permacol® patch used in a neonatal CDH repair 2 
months after placement  to show tissue incorporation 
Permacol®, less widely used in CDH applications but popularized in adults, is an 
extracelluar matrix of chemically crosslinked porcine dermal collagen. In a case report of 
abdominovisceral disproportion and a retrospective CDH series, Permacol® demonstrated 
durability with no recurrences in a median follow up of 20 months, the time frame in which 
Gore-Tex® demonstrated a 28% failure rate (Richards et al., 2005; Mitchell et al., 2008). The 
type of tissue incorporation with Permacol® is illustrated in Figure 2 above, in a baby 2 
months following a CDH repair with Permacol. This is an intrathoroscopic caudal view at 
the diaphragm due a second surgery for a previously unrecognized lung anomaly; no suture 
line is evident here which is so evident with the use of a synthetic. Also there are multiple 
areas of tissue ingrowth from the side of the Permacol against the liver (note red punctate 
areas as islands of tissue ingrowth). The cross-linking of lysine and hydroxylysine residues 
within the collagen fibers of Permacol® imparts a higher resistance to collagenases and 
improved durability compared to other bioprosthetics (Richards, et al. 2005).  
Composite patch repairs, such as Gore-Tex®/Marlex synthetic patches, have been reported 
used in humans with only a 3% recurrence rate, followed for a median of 47 months, but 
had an unusual comorbidity of a 17% splenectomy rate which is nontrivial in this 
population (Riehle et al., 2007). The search for an ideal material for CDH repairs is an 
ongoing active area of investigation. Clearly controlled trials are needed to compare the 
outcomes from composite grafts (such as Gore-Tex® with a bioprosthetic) to other 
bioprosthetics and synthetics; likewise bioengineered grafts are potentially promising. 
3.3 Autologous grafts 
Autologous tissue is often limited in size and viability in a neonate, as well as problematic 
given the heparinization needed for possible ECMO. Often autologous tissue is not ideal for 
initial repair. Thus, autologous tissue is used for more often in the setting of staged repair, 
recurrent reherniation or when a child is older and the tissue is more robust or of sufficient 
size. The first patch repair described for a CDH repair used autologous tissue and a split 
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abdominal wall muscle flap (Simpson & Gossage, 1971). The split abdominal wall muscle 
flap was idealized to place a vascularized and innervated tissue flap repair that will both 
accommodate growth and cover a large diaphragmatic defect. This flap has not been 
popularized and thus remains as infrequently used option. A single institution series 
retrospectively reviewed their use: in 13 patients, 5 of which were done on ECMO, there 
were no recurrences in 6 years excluding the one patient dying in the ECMO subset from 
right heart failure (Brant- Zawadzki et al., 2007). The muscle flap has yet to gain widespread 
acceptance as a first- line procedure (Nasr et al., 2010) and is often reserved for an older 
child with greater muscle capacity and robustness (Masumoto et al., 2007). 
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Table 2. Autologous muscle or fascial flaps 
Other autologous grafts are utilized for the repair of the recurrent CDH and include the 
reversed latissimus dorsi muscle flap (Sydorak et al., 2003); and the free fascia lata repair 
(Sugiyama et al., 2011). The reversed latissimus dorsi muscle flap is both vascularized and 
innervated and has shown promise in 7 patients with no reherniation in a medium follow 
up of 24 months (Sydorak et al., 2003). This use of autologous tissue is best utilized for the 
repair of recurrences, and allows not only a pleuroperitoneal separation, but also a 
potentially functional diaphragmatic reconstruction: this later point needs to be proven in 
longterm studies given the neural anastomosis. The free fascia lata graft has the potential of 
using the strongest fascia but may result in loss of extremity function, is not innervated, and 
its application in children or neonates is not well popularized. All autologous tissue repairs 
can be problematic if utilized in the setting of a heparinized circuit such as ECMO, 
particularly with a large surface area of dissection with associated tissue edema. All of these 
autologous grafts are cautioned to be used with a liberal application of a staged abdominal 
wall closure, particularly in those on ECMO support with resultant significant tissue edema. 
4. Impact of minimally invasive surgery on recurrences 
The revolution in minimally invasive surgery (MIS) naturally allowed the application of 
MIS to the repair of CDH patients. Theoretically, a minimally invasive repair would 
minimize the deleterious effects of open surgery while being able to decompress the CDH 
lung. Many reports have proclaimed the feasibility and initial safety of MIS in its application 
to CDH repairs (Yang et al., 2005; Shah et al., 2009).  
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Since the technique is relatively new, there was a careful case selection bias in order to select 
those patients most suitable. Despite a case selection bias, there is already a significant 
incidence of recurrences in those repaired by MIS, as opposed to those undergoing an open 
repair, when examining 151 MIS repairs in the CDH registry out of a total of 4516 patients 
repaired (Tsao & Lally et al., 2011). Case selection was intended and evident in the disparate 
use of ECMO (Cho et al., 2009) and targeting groups with favorable criteria such as 
ventilator stability and absence of stomach or liver herniation (Yang et al., 2005; Kim et al., 
2009). Thus, the higher in-hospital recurrence rates will need to be analyzed over longterm 
to evaluate outcomes. A meta-analysis of thoracoscopic neonatal CDH repairs illustrated 
that a thoracoscopic repair is associated with a 3-fold increased recurrence rate and longer 
operative times, although the mortality rate was similar in open and thoracoscopic repairs 
(Lansdale et al., 2010). Potentially, the thorocoscopic approach does not allow sufficient 
mobilization of the posterior leaflet of the diaphragm, committing more patients to 
prosthetic graft repairs overall.  
5. Conclusion 
In summary given the heterogeneity of disease severity, the complexity of CDH repairs has 
not been able to be prognostically separated into clear risk-stratified groups preoperatively 
to appropriately match for the therapies best suited to a category of risk. Now that the 
relationship of defect size to incidence of patch severity has been established, it is clear that 
many strategies are needed to best benefit those with the greatest defects and the worst 
CDH severity, both in the short term and long term. Composite bioprosthetic grafts and 
biologics have shown promise. 
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